Executive SummaryNoteworthy news from medtech start-ups. This month's we feature Aleva Neurotherapeutics, whose electrodes enable precise and target-specific deep brain stimulation, and cermaVEIN, which is developing steam ablation technology for treating varicose veins.
You may also be interested in...
The company is looking at deals in the $2bn to $5bn range, CEO Paul Hudson told investors, but premiums for assets are high and Sanofi is looking at earlier-stage opportunities as a result.
The physician who led the first first-in-human robotic-assisted neurovascular intervention with Corindus’ CorPath GRX system believes the technology could revolutionize neurovascular intervention by allowing a centralized interventional team to remotely treat patients.